Please Wait
Applying Filters...
menu
    • menu
    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Varespladib Methyl

    DEVELOPMENTS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 172733-08-3, Ly333013, Ly-333013, A-002, Varespladib methyl ester, S-3013
    Molecular Formula
    C22H22N2O5
    Molecular Weight
    394.4  g/mol
    InChI Key
    VJYDOJXJUCJUHL-UHFFFAOYSA-N
    FDA UNII
    0NB98NBX3D
    Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    methyl 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetate
    2.1.2 InChI
    InChI=1S/C22H22N2O5/c1-3-15-20(21(26)22(23)27)19-16(24(15)12-14-8-5-4-6-9-14)10-7-11-17(19)29-13-18(25)28-2/h4-11H,3,12-13H2,1-2H3,(H2,23,27)
    2.1.3 InChI Key
    VJYDOJXJUCJUHL-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)OC)C(=O)C(=O)N
    2.2 Other Identifiers
    2.2.1 UNII
    0NB98NBX3D
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. A-002

    2. Ly-333013

    3. Ly333013

    4. Methyl ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)acetate

    5. S-3013

    6. S3013

    2.3.2 Depositor-Supplied Synonyms

    1. 172733-08-3

    2. Ly333013

    3. Ly-333013

    4. A-002

    5. Varespladib Methyl Ester

    6. S-3013

    7. Varespladib Methyl [usan]

    8. 0nb98nbx3d

    9. Ly 333013

    10. S 3013

    11. Methyl ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)acetate

    12. Varespladib Methyl (usan)

    13. Methyl ({3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1h-indol-4-yl}oxy)acetate

    14. Methyl-varespladib

    15. Acetic Acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)-, Methyl Ester

    16. Methyl 2-((3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1h-indol-4-yl)oxy)acetate

    17. Unii-0nb98nbx3d

    18. Methyl Varespladib

    19. Varespladib-methyl

    20. Schembl25678

    21. Chembl2105659

    22. Dtxsid40938196

    23. Chebi:192805

    24. Xga73308

    25. Zinc1550156

    26. Varespladib Methyl Ester [mi]

    27. Akos037643560

    28. Cs-6574

    29. Db05737

    30. Sb16537

    31. Ncgc00387871-03

    32. As-16898

    33. Hy-17448

    34. D08221

    35. Q7915615

    36. Methyl 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetate

    37. Methyl ((3-(aminooxoacetyl)-1-benzyl-2-ethyl-1h-indol-4-yl)oxy)acetate

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 394.4 g/mol
    Molecular Formula C22H22N2O5
    XLogP33.1
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count9
    Exact Mass g/mol
    Monoisotopic Mass g/mol
    Topological Polar Surface Area101
    Heavy Atom Count29
    Formal Charge0
    Complexity604
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for use/treatment in atherosclerosis and coronary artery disease.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Phospholipase A2 Inhibitors

    Compounds that inhibit or block the activity of a PHOSPHOLIPASE A2 enzyme. (See all compounds classified as Phospholipase A2 Inhibitors.)

    5.2 Mechanism of Action

    A002 is an orally administered potent inhibitor of secretory phospholipase spla2(spla2) including groups IIA V and X. Atherosclerosis is a disease of the arteries that results from inflammation and the build-up of plaque under the lining of the blood vessel. This build-up can cause vascular swelling and eventual rupture. spla2 levels have been shown to be elevated in patients with both stable and unstable coronary artery disease. Higher levels of the enzyme have been shown to predict an increased risk for future cardiovascular events such as heart attacks and stroke.